Navigation Links
Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
Date:2/12/2008

- Lead Clinical Program and Two Clinical Candidates Featured -

SOUTH SAN FRANCISCO, Calif., Feb. 12 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, announced four abstracts have been selected for presentation at the meeting of American Association for Cancer Research being held in San Diego on April 12-16, 2008.

"We are pleased to have this opportunity to present important data on both RAV12, Raven's lead therapeutic antibody entering Phase 2 development for the treatment of adenocarcinomas and the promising near-term clinical candidates in our oncology pipeline," stated George Schreiner, M.D., Ph.D., chief executive officer of Raven biotechnologies. "Raven will present significant new data on RAV12 supporting the chemotherapeutic synergies that inform its impending phase 2 trials. In addition, recent discoveries concerning novel epitopes and effector mechanisms associated with two new antibodies targeting cancer stem cells will be presented for the first time. Both antibodies are slated for clinical development. Finally, having advanced the technology to culture cancer stem cells on a sustained basis in vitro, we will present their in vivo biology, using prostate cancer stem cells as an important new model system for understanding the growth and metastasis of human cancer."

The presentations are scheduled as follows:

Oral Presentation in a Minisymposium Session

The anti-B7-H3-4Ig antibody TES7 recognizes cancer stem cell lines, modulates angiogenic factor secretion, and exhibits potent anti-tumor activity in vivo

Session ID: Experimental and Molecular Therapeutics 24

Date and Time: Monday, April 14, 2008, 1:00 PM

Abstract Number: 2555

Poster Sessions

Human prostate cancer stem cell line spontaneously metastasizes in vivo

Session ID: Tumor
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
2. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
3. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
10. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
11. Amyris Biotechnologies Announces $70 Million Series B Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Burkina Faso (PRWEB) July 10, 2014 ... Faso, today have access to an additional family ... increase access to contraception at all levels of ... a lower-dose formulation of a widely used contraceptive—Pfizer’s ... system. , Burkina Faso is the first of ...
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, ... Family purchased a DNA test to unravel ... with a lifetime of memories, sharing, and closeness. In ... DNA genuinely brought the family closer together. , ... genetic history and prior to taking the genetic ...
(Date:7/10/2014)... CROWN POINT, Ind. , July 10, ... recently expanded its use of capnography for ... a growing group of healthcare leaders in ... Capnography measures how effectively patients are breathing ... respiratory depression occurs. By measuring the amount ...
(Date:7/10/2014)... --  Ceres, Inc . (Nasdaq: CERE ), ... results for the three months ended May 31, 2014 ... Ceres reported that the company and its customers have ... in Brazil, which concluded in June, despite dry and ... for part of the growing season. Yields of several ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... , BEIJING, Sept. 16 ... hospital groups, has announced it will broaden inclusion,criteria ... study will use,stem cells derived from peripheral blood ... of diabetic foot ulcers involves intensive,wound management, risk ...
... 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, today announced ... its partner and licensee for perifosine in the North ... from the U.S. Food and Drug Administration (FDA) for ...
... , , , SAN ... it is relaunching its oligonucleotide radiolabeling services. TriLink discontinued the ... that the market may no longer require it. However, strong ... in September 2009. , , "We,ve learned ...
Cached Biology Technology:Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 2Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 3Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 4AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services 2
(Date:7/14/2014)... an inevitable consequence of aging? , Although it is ... aging, the risk of developing several common cancers decreases ... the apparent decrease with age in the risk of ... to this puzzle was presented in a recent paper ... Professor James P. Brody of the Department of Biomedical ...
(Date:7/14/2014)... make in the laboratory all of the different types of ... reality. , Writing today in the journal Nature Communications ... researcher Igor Slukvin reports the discovery of two genetic programs ... both red and the array of white cells that make ... identifies how nature itself makes blood products at the earliest ...
(Date:7/11/2014)... from the Wildlife Conservation Society shows that no-take ... valuable species such as lobster, conch, and fish ... nearby reef areas. , The reporttitled "Review of ... of research literature from no-take areas around the ... Dahlgren, a recognized expert in marine protected areas ...
Breaking Biology News(10 mins):Wisconsin scientists find genetic recipe to turn stem cells to blood 2Wisconsin scientists find genetic recipe to turn stem cells to blood 3Belize's lobster, conch, and fish populations rebuild in no-take zones 2
... space activities, a silent revolution is taking place at ... first human-rated spacecraft to be launched from Europe,s Spaceport, ... pressurised module of the largest, most complex automated spacecraft ... fulfilling the most stringent rules of human spaceflight. , ...
... to pass genes to the next generation. In sexually ... that are vital for fertility. In a new study ... researchers at Cornell University knocked down the levels of ... the males abilities to modulate egg production, sperm storage ...
... Washington University School of Medicine in St. Louis have ... plague women with urinary tract infections (UTIs) are entrenched ... controversial revision of scientists, model of how bacteria cause ... for infections get into the bladder but do not ...
Cached Biology News:Final preparations for first human-rated spacecraft to be lauched from Europe's Spaceport 2Final preparations for first human-rated spacecraft to be lauched from Europe's Spaceport 3Bacteria that cause urinary tract infections invade bladder cells 2Bacteria that cause urinary tract infections invade bladder cells 3
...
...
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
Poly A Polymerase catalyzes the addition of AMP to the 3' hydroxyl terminus of RNA. Poly A Polymerase can add poly(C) and poly(U) to RNA but does so with much-reduced efficiency....
Biology Products: